These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17936214)

  • 21. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
    Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
    Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure.
    Ghijsels E; Lerut E; Vanrenterghem Y; Kuypers D
    Am J Kidney Dis; 2004 May; 43(5):e34-8. PubMed ID: 15112197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
    Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
    Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Kidney involvement in mixed cryoglobulinemia: which treatment?].
    Cacoub P
    Presse Med; 2012 Mar; 41(3 Pt 1):254-9. PubMed ID: 22192935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in mixed cryoglobulinemia: increased experience and perspectives.
    De Vita S; Quartuccio L; Fabris M
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S122-8. PubMed ID: 17936213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
    Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
    Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
    Sneller MC; Hu Z; Langford CA
    Arthritis Rheum; 2012 Mar; 64(3):835-42. PubMed ID: 22147444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia.
    Sansonno D; Tucci FA; Troiani L; Sansonno L; Dammacco F
    Curr Med Chem; 2008; 15(2):117-26. PubMed ID: 18220767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
    Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
    Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
    Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S
    Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemia.
    da Silva Fucuta Pereira P; Lemos LB; de Oliveira Uehara SN; de Souza E Silva IS; Silva AE; Ferraz ML
    Rheumatol Int; 2010 Sep; 30(11):1515-8. PubMed ID: 19705122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.
    Mathur P; Emmanuel B; Sneller M; Zhang X; Poonia B; Kottilil S
    J Med Virol; 2018 May; 90(5):936-941. PubMed ID: 29236302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Emmanuel B; Sidique N; Zhang X; Poonia B; Sneller MC; Kottilil S
    J Viral Hepat; 2017 Feb; 24(2):128-131. PubMed ID: 27666584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study.
    Ammendola S; Romeo S; Cattazzo F; Mantovani A; Ieluzzi D; Paon V; Montagnana M; Pecori S; Tomezzoli A; Dalbeni A; Sacerdoti D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
    Roccatello D; Fenoglio R; Sciascia S
    Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab.
    Baerlecken NT; Schmidt RE
    Clin Rheumatol; 2013 Mar; 32 Suppl 1():S19-20. PubMed ID: 20213127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
    Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
    Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.